07.13.10
KD-Pharma, a subsidiary of Bioseutica, has introduced customized combinations of omega 3 EPA/DHA at concentrations of up to 99% produced through the company’s patented kd-pur manufacturing process. The process can remove undesired components from omega 3s such as omega 6, saturated fats, cholesterol and contaminants. This means that every dose of kd-pur omega 3 products has less interference from undesired components, which would translate into better metabolic and therapeutic activity, and a better safety profile. Varying the ratio of EPA and DHA allows the company to target specific health conditions including cardiovascular, brain function and the anti-inflammatory category. For further information: www.kd-pharma.us